

Genetic and Epigenetic Signature Identifies Individuals with Elevated Response to Vitamin B12 Supplementation

Jessie Nicodemus Johnson, PhD and Mark Brown, PhD

USANA Health Sciences, 3838 West Parkway Boulevard Salt Lake City UT, 84120



Abstract

Vitamin B₁₂ is essential for many aspects of human health. Deficiencies are largely caused by inadequate intake or reduced absorption, and are associated with increased incidence of neurological, cognitive and cardiovascular decline [1]. Using a previously published dataset of B₁₂/folic acid supplementation in elderly individuals (GSE74548), we investigated the effect of a variant in the *methylenetetrahydrofolate reductase* gene (*MTHFR*; rs1801133) on serum B₁₂ and folate levels at baseline and after 2 years of supplementation. As well as, the association between baseline genome-wide DNA methylation (Infinium 450K DNA methylation chip) in peripheral blood mononuclear cells (PBMCs) and supplementation induced changes in circulating B vitamin levels. Among post-supplementation individuals, we observed that those with the rs1801133 CC genotype had elevated circulating B₁₂ but not folic acid levels, relative to the rs1801133 TT genotype (P = 0.0073 and P = 0.47, respectively). Moreover, individuals with the CC genotype clustered into two distinct B₁₂ response groups (P = 2.8 x10⁻⁶), termed high and low responders. Additionally, we observed an enrichment of low p-values among baseline DNA methylation patterns and change in circulating B₁₂ levels after supplementation in CC individuals only (empirical P < 1x10⁻⁵). This epigenetic signature is not near genetic variants or genes known to influence vitamin B₁₂ uptake. Overall, we present evidence that epigenetic signatures at baseline may predict an individual's response to B₁₂ supplementation and may highlight novel pathways associated with elevated response to B₁₂ supplementation, may aid in the treatment of chronically deficient individuals.

Methods

- B -Vitamins for the PRevention of Osteoporotic Fractures
- Randomized, placebo-controlled trial (GSE74548) [2]
- Two year daily supplementation with 400ug folic acid/500ug vitamin B12 (N=44) or placebo (N=43)
- DNA for genome-wide DNA methylation (Infinium 450K Bead Chip) and serum for folic acid/ vitamin B12 collected at baseline and 2 year follow-up from buffy coats
- Correlations between quantile transformed serum folic acid/ vitamin B12 levels and DNA methylation at baseline (N=8,036 CpG sites) were determined using standard linear regression in R v3.3.1

Figure 1. Serum vitamin B₁₂, but not folate levels vary by rs1801133 genotype after supplementation

Stratification of serum B₁₂ levels by *methylenetetrahydrofolate reductase* (*MTHFR*) rs1801133 genotype and supplementation status for serum B₁₂ levels (**A**) and folate (**B**). After supplementation, serum B₁₂, not folate, levels are significantly different by genotype (P = 0.047 and 0.0073, respectively). *MTHFR* CC individuals cluster into 2 distinct groups, that may represent high and low responders to supplementation (P = 2.8x10⁻⁶). High responders (light blue dots) are significantly different from the rs1801133 TT individuals (black dots; P = 6.9x10⁻⁷), as opposed to low responders (dark blue dots; P=1). P-values were generated using Wilcoxon Rank sum test and vitamin B₁₂/folate serum values.




Figure 2. Baseline DNA methylation levels are correlated with supplementation induced changes in serum vitamin B₁₂

A. Density plot of Spearman correlation p-value distributions for rs1801133 CC (blue line) and TT individuals (dashed line). rs1801133 CC individuals are enriched for low p-values (P < 0.01) (empirical P < 1 x10⁻⁵). rs1801133 TT individuals are modestly enriched for low p-values (empirical P=0.044). **B.** Among rs1801133 CC individuals, baseline serum vitamin B₁₂ levels are modestly elevated in high responders relative to low responders (P=0.13). **C.** Scatterplot of median DNA methylation foldchange (baseline - follow-up) for rs1801133 CC individuals receiving placebo (y-axis) or supplementation (x-axis). Red dots





Figure 3. Genes near correlated CpG sites (p < 0.01) are enriched in inflammatory and immunomodulatory pathways

Genes near correlated CpG sites are significantly enriched in two Ingenuity Pathway Analysis protein-protein interaction networks. **A.** The first network (score = 46) is centered around the major inflammatory transcription factor, *NFkB*. **B.** The second network (score = 43) is centered around many interacting immunomodulatory molecules. *ITGB1* (*CD29*), for example, has been linked to enhanced immune cell ability to respond to recall antigens and home to sites of infection [3]. Molecules shaded in grey represent genes that are near a CpG site in which baseline DNA methylation levels are correlated with supplementation induced changes in serum B₁₂ (P < 0.01).



Conclusions

- Genetic and baseline epigenetic signatures detectable in blood are correlated with and may be able to predict response to vitamin B₁₂ supplementation
- This baseline epigenetic signature may alter the ability of immune cells to respond to inflammatory or immunomodulatory stimuli

References

1. Porter, K., et al., *Causes, Consequences and Public Health Implications of Low B-Vitamin Status in Ageing*. Nutrients, 2016. **8**(11).
2. Kok, D.E., et al., *The effects of long-term daily folic acid and vitamin B12 supplementation on genome-wide DNA methylation in elderly subjects*. Clin Epigenetics, 2015. **7**: p. 121.
3. Morimoto, C., et al., *The isolation and characterization of the human suppressor inducer T cell subset*. J Immunol, 1985. **134**(3): p. 1508-15.